Posted by Michael Wonder on 28 Sep 2017
AbbVie announces global resolution of Humira (adalimumab) patent disputes with Amgen
28 September 2017 - Agreements provide non-exclusive license to Amgen for Humira related intellectual property in the U.S. effective 31 January 2023, and in other markets on different dates.
AbbVie announced today a global resolution of all intellectual property-related litigation with Amgen over Amgen's proposed biosimilar adalimumab product.
Under the terms of the settlement agreements, AbbVie will grant to Amgen a non-exclusive license to AbbVie's intellectual property relating to Humira beginning on certain dates in certain countries in which AbbVie has intellectual property. The license period will begin on 31January 2023 in the U.S., on 16 October 2018 in most countries in the European Union, and on other dates in various countries in which AbbVie has intellectual property. Amgen will pay royalties as specified under the agreements. The precise terms are confidential between the parties. All litigation pending between the parties will be dismissed, and Amgen has acknowledged the validity of AbbVie's intellectual property related to Humira.
